Tyrosine News and Research

RSS

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

30 May 2015

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.

30 May 2015

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

BerGenBio AS, an oncology biopharmaceutical company, today announces that an abstract on the latest data on BGB324, the Company's first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29 - June 2, 2015.

30 May 2015

SNPs predict sunitinib outcome in mRCC

Research has confirmed that single nucleotide polymorphisms in genes related to the processing of sunitinib influence the outcome of treatment for metastatic renal cell carcinoma.

29 May 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests.

29 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Novel drug target identified for treating rheumatoid arthritis

Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints.

21 May 2015

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

Merus and Selexis will combine their unique and proprietary Oligoclonics® and SUREtechnology™ platforms respectively to develop a product combining two bispecific full length IgG antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases...

20 May 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Promising preliminary results for AKB-9778 in diabetic macular oedema

AKB-9778, a small molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase, has a good safety and efficacy profile in patients with diabetic macular oedema, suggests a preliminary dose-escalation study.

19 May 2015

Scientists uncover mechanism behind 'tubulin code'

Driving down the highway, you encounter ever-changing signs -- speed limits, exits, food and gas options. Seeing these roadside markers may cause you to slow down, change lanes or start thinking about lunch. In a similar way, cellular structures called microtubules are tagged with a variety of chemical markers that can influence cell functions.

13 May 2015

TSRI scientists map out protein structure involved in cellular function, nervous system development

Scientists from The Scripps Research Institute, working closely with researchers at the National Institutes of Health, have mapped out the structure of an important protein involved in cellular function and nervous system development.

12 May 2015

UM cell biologist advances research about behavior of cell proteins in neuroblastoma

Patience and persistence are beginning to pay off for University of Montana Professor Mark Grimes, whose research about the behavior of cell proteins in childhood cancer recently was published by the Public Library of Science Computational Biology.

From Cell Signaling Technology 10 May 2015

Discovery may have opened up new frontier in fight against breast cancer

For years, scientists have been puzzled by the presence of short stretches of genetic material floating inside a variety of cells, ranging from bacteria to mammals, including humans. These fragments are pieces of the genetic instructions cells use to make proteins, but are too short a length to serve their usual purpose.

8 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Tyrosine News and Research

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

SNPs predict sunitinib outcome in mRCC

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Novel drug target identified for treating rheumatoid arthritis

Merus and Selexis receive a € 2.1 million grant for single cell line manufacturing of a bispecific antibody combination to treat colorectal cancer

No added benefit with pazopanib over ranibizumab for neovascular AMD

Promising preliminary results for AKB-9778 in diabetic macular oedema

Scientists uncover mechanism behind 'tubulin code'

TSRI scientists map out protein structure involved in cellular function, nervous system development

UM cell biologist advances research about behavior of cell proteins in neuroblastoma

Discovery may have opened up new frontier in fight against breast cancer

Researchers identify multiple types of resistance to new targeted lung cancer drug

ITIM-containing receptor crucial for development of acute myeloid leukemia

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

CML guidelines highlight need for TKI switch timing, choice

Novel treatment strategy targets treatment-resistant CML

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News